Julien Flament
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Julien Flament has a total of 229 co-authors. Here are the top co-authors by number of shared publications:
Philippe Hantraye
Université Paris-Saclay, Centre National de la Recherche Scientifique, Commissariat à l’Energie Atomique, Neurodegenerative Diseases Laboratory (UMR9199), Molecular Imaging Research Center (MIRCen) , Fontenay-aux-Roses F-92265
15 shared publications- Julien Valette
Commissariat à l'Energie Atomique et aux Energies Alternatives, Centre National de la Recherche Scientifique, Molecular Imaging Research Center, Laboratoire des Maladies Neurodégénératives, Université Paris-Saclay, Fontenay-aux-Roses, France
14 shared publications - Emmanuel Brouillet
Université Paris-Saclay, Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Centre National de la Recherche Scientifique (CNRS), Molecular Imaging Research Center (MIRCen), Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France
10 shared publications - Carole Escartin
Université Paris‐Saclay, CNRS, NeuroPSI Saclay France
6 shared publications Emmanuel Brouillet
Laboratoire des Maladies Neurodégénératives, Molecular Imaging Research Center, Commissariat à l’Energie Atomique et aux Energies Alternatives, Centre National de la Recherche Scientifique, Université Paris-Saclay, Fontenay-aux-Roses, France
6 shared publications- Marc Dhenain
Neuro-Bicêtre, Inserm U1195, CNRS EMR2000, Université Paris-Saclay, Bâtiment Gregory Pincus, Le Kremlin Bicêtre, France
6 shared publications
Latest Publications
- 30 March 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Développement de l'imagerie RMN par agents CEST : application à un modèle rongeur de tumeur cérébrale
L’objectif de cette thèse est de développer l’imagerie de transfert de saturation des agents de contraste lipoCEST pour la détection de l’angiogenèse dans un modèle souris de tumeur cérébrale U87. Un lipoCEST offrant un seuil de sensibilité in vitro de 100 pM est optimisé afin de répondre aux contraintes de l’imagerie CEST in vivo. Grâce à la mise en place d’un dispositif expérimental dédié à l’imagerie CEST, nous évaluons les performances des lipoCEST pour détecter de façon spécifique l’angiogenèse tumorale. Nous montrons pour la première fois qu’il est possible de détecter un lipoCEST in vivo dans un cerveau de souris suite à une injection intraveineuse. De plus, l’utilisation d’un lipoCEST fonctionnalisé avec un peptide RGD permet de cibler spécifiquement l’intégrine ανβ3 surexprimée lors de l’angiogenèse tumorale. L’association spécifique du RGD-lipoCEST est confirmée grâce à des données d’immunohistochimie et de microscopie de fluorescence. Enfin, dans le but de tendre vers un protocole d’imagerie moléculaire par IRM-CEST, nous mettons en place un outil de quantification des lipoCEST. Cet outil repose sur la modélisation des processus d’échange de protons in vivo. Grâce à la prise en compte des inhomogénéités de champs B0 et B1 qui peuvent se révélées être délétères pour le contraste CEST, nous démontrons que la précision de notre outil de quantification est de 300 pM in vitro. La quantification des données CEST acquises chez la souris U87 permet d’estimer à 1,8 nM la concentration maximale en RGD-lipoCEST liés à leur cible moléculaire.
- 30 March 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Développement de l'imagerie RMN par agents CEST : application à un modèle rongeur de tumeur cérébrale
L’objectif de cette thèse est de développer l’imagerie de transfert de saturation des agents de contraste lipoCEST pour la détection de l’angiogenèse dans un modèle souris de tumeur cérébrale U87. Un lipoCEST offrant un seuil de sensibilité in vitro de 100 pM est optimisé afin de répondre aux contraintes de l’imagerie CEST in vivo. Grâce à la mise en place d’un dispositif expérimental dédié à l’imagerie CEST, nous évaluons les performances des lipoCEST pour détecter de façon spécifique l’angiogenèse tumorale. Nous montrons pour la première fois qu’il est possible de détecter un lipoCEST in vivo dans un cerveau de souris suite à une injection intraveineuse. De plus, l’utilisation d’un lipoCEST fonctionnalisé avec un peptide RGD permet de cibler spécifiquement l’intégrine ανβ3 surexprimée lors de l’angiogenèse tumorale. L’association spécifique du RGD-lipoCEST est confirmée grâce à des données d’immunohistochimie et de microscopie de fluorescence. Enfin, dans le but de tendre vers un protocole d’imagerie moléculaire par IRM-CEST, nous mettons en place un outil de quantification des lipoCEST. Cet outil repose sur la modélisation des processus d’échange de protons in vivo. Grâce à la prise en compte des inhomogénéités de champs B0 et B1 qui peuvent se révélées être délétères pour le contraste CEST, nous démontrons que la précision de notre outil de quantification est de 300 pM in vitro. La quantification des données CEST acquises chez la souris U87 permet d’estimer à 1,8 nM la concentration maximale en RGD-lipoCEST liés à leur cible moléculaire.
- 10 June 2025
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (12) , 125005
Improved feedback loop control for ultrasound-assisted blood–brain barrier opening in non-human primates based on the discrimination between intra- and extra-cerebral cavitation
Objective. Temporary, non-invasive, and localized permeabilization of the blood–brain barrier (BBB) can be achieved through focused ultrasound and microbubbles (MB). This technique has been extensively employed in rodent and non-human primate (NHP) studies for testing various drugs but requires precise control of ultrasonic pressure. However, controlling cavitation in NHP is challenging due to their thicker skull inducing strong ultrasonic attenuation. Furthermore, extra-cranial cavitation may occur masking the cavitation signal at the focal region (cerebral cavitation). Particularly in larger male NHP, temporal muscles are highly perfused and filled with MB. Approach. This study proposes a feedback loop control strategy to distinguish between intra- and extra-cerebral cavitation by analyzing broadband noise recorded by passive cavitation detection sensors. Main results. The frequency-dependent low-pass filtering effect by the skull allows differentiation of distinct frequency components, providing insights into cavitation origin. The present study involved 17 BBB opening experiments in NHP. Significance. Although successful BBB disruption can be achieved in NHP with thin temporal muscles (15 mm) require the use of an optimized algorithm able to specifically extract the signature of intra-cerebral cavitation.
- 10 June 2025
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (12) , 125005
Improved feedback loop control for ultrasound-assisted blood–brain barrier opening in non-human primates based on the discrimination between intra- and extra-cerebral cavitation
Objective. Temporary, non-invasive, and localized permeabilization of the blood–brain barrier (BBB) can be achieved through focused ultrasound and microbubbles (MB). This technique has been extensively employed in rodent and non-human primate (NHP) studies for testing various drugs but requires precise control of ultrasonic pressure. However, controlling cavitation in NHP is challenging due to their thicker skull inducing strong ultrasonic attenuation. Furthermore, extra-cranial cavitation may occur masking the cavitation signal at the focal region (cerebral cavitation). Particularly in larger male NHP, temporal muscles are highly perfused and filled with MB. Approach. This study proposes a feedback loop control strategy to distinguish between intra- and extra-cerebral cavitation by analyzing broadband noise recorded by passive cavitation detection sensors. Main results. The frequency-dependent low-pass filtering effect by the skull allows differentiation of distinct frequency components, providing insights into cavitation origin. The present study involved 17 BBB opening experiments in NHP. Significance. Although successful BBB disruption can be achieved in NHP with thin temporal muscles (15 mm) require the use of an optimized algorithm able to specifically extract the signature of intra-cerebral cavitation.
- 5 February 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 148 (7) , 2453-2468
Loss of the neuronal kinase DCLK3 leads to anxiety-like behaviour and memory deficits
DCLK3 (Doublecortin-like kinase 3) is a kinase preferentially expressed in neurons. Dclk3 variants are risk factors for psychiatric disorders and brain alterations linked to age-related mild cognitive impairment, suggesting that this kinase could be important to cognition. However, the physiological role of DCLK3 remains unknown. Here, we generated and characterized mice with constitutive or brain region-specific Dclk3 knockout. We found that constitutive pan-deletion of Dclk3 is associated with an anxiety phenotype in males, associated with changes in brain metabolites in the absence of major neuroanatomical alterations, motor deficits or memory deficits. Moreover, virally mediated loco-regional conditional Dclk3 knockout in the dorsal hippocampus of adult mice led to spatial memory deficits and transcriptomic changes, characterized by increased expression of α2, β1 and β2 subunits of the GABAA receptor, downregulation of neuronal activity-regulated genes, such as the immediate early genes (e.g. Egr1, Fos, Per1 and Nr4r1), and transcriptional regulator activity enriched in polycomb-repressive complexes. These new data reveal that Dclk3 modulates behaviour and cognition in association with transcriptomic changes in the hippocampus, providing direct physiological evidence that this kinase is involved in synaptic plasticity, consistent with its crucial role in neurodegenerative and psychiatric diseases.
- 5 February 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 148 (7) , 2453-2468
Loss of the neuronal kinase DCLK3 leads to anxiety-like behaviour and memory deficits
DCLK3 (Doublecortin-like kinase 3) is a kinase preferentially expressed in neurons. Dclk3 variants are risk factors for psychiatric disorders and brain alterations linked to age-related mild cognitive impairment, suggesting that this kinase could be important to cognition. However, the physiological role of DCLK3 remains unknown. Here, we generated and characterized mice with constitutive or brain region-specific Dclk3 knockout. We found that constitutive pan-deletion of Dclk3 is associated with an anxiety phenotype in males, associated with changes in brain metabolites in the absence of major neuroanatomical alterations, motor deficits or memory deficits. Moreover, virally mediated loco-regional conditional Dclk3 knockout in the dorsal hippocampus of adult mice led to spatial memory deficits and transcriptomic changes, characterized by increased expression of α2, β1 and β2 subunits of the GABAA receptor, downregulation of neuronal activity-regulated genes, such as the immediate early genes (e.g. Egr1, Fos, Per1 and Nr4r1), and transcriptional regulator activity enriched in polycomb-repressive complexes. These new data reveal that Dclk3 modulates behaviour and cognition in association with transcriptomic changes in the hippocampus, providing direct physiological evidence that this kinase is involved in synaptic plasticity, consistent with its crucial role in neurodegenerative and psychiatric diseases.
- Open Access
- 21 November 2024
- Published by Wiley in NMR in Biomedicine
- Vol. 38 (3) , e5297
Noninvasive Imaging of Transgene Expression in Neurons Using Chemical Exchange Saturation Transfer MRI
Advances in gene therapy, especially for brain diseases, have created new imaging demands for noninvasive monitoring of gene expression. While reporter gene imaging using co‐expression of fluorescent protein–encoding gene has been widely developed, these conventional methods face significant limitations in longitudinal in vivo applications. Magnetic resonance imaging (MRI), specifically chemical exchange saturation transfer (CEST) MRI, provides a robust noninvasive alternative that offers unlimited depth penetration, reliable spatial resolution, and specificity toward particular molecules. In this study, we explore the potential of CEST‐MRI for monitoring gene expression in neurons. We designed a CEST polypeptide reporter expressing 150 arginine residues and evaluated its expression in the living brain after viral vector delivery. A longitudinal study performed at one and 2 months postinjection showed that specific CEST signal was observable. In particular, the CEST contrast exhibited distinct peaks at 0.75 and 1.75 ppm, consistent with the expected hydroxyl and guanidyl protons resonance frequencies. Histological study confirmed the specific neuronal expression of the transgene evidenced by the fluorescence signal from the td‐Tomato fluorophore fused to the polypeptide. The ability to image noninvasively a neuron‐specific CEST‐MRI reporter gene could offer valuable insights for further developments of gene therapy for neurological disorders.
- 21 November 2024
- Published by Wiley in NMR in Biomedicine
- Vol. 38 (3) , e5297
Open AccessNoninvasive Imaging of Transgene Expression in Neurons Using Chemical Exchange Saturation Transfer MRI
Advances in gene therapy, especially for brain diseases, have created new imaging demands for noninvasive monitoring of gene expression. While reporter gene imaging using co‐expression of fluorescent protein–encoding gene has been widely developed, these conventional methods face significant limitations in longitudinal in vivo applications. Magnetic resonance imaging (MRI), specifically chemical exchange saturation transfer (CEST) MRI, provides a robust noninvasive alternative that offers unlimited depth penetration, reliable spatial resolution, and specificity toward particular molecules. In this study, we explore the potential of CEST‐MRI for monitoring gene expression in neurons. We designed a CEST polypeptide reporter expressing 150 arginine residues and evaluated its expression in the living brain after viral vector delivery. A longitudinal study performed at one and 2 months postinjection showed that specific CEST signal was observable. In particular, the CEST contrast exhibited distinct peaks at 0.75 and 1.75 ppm, consistent with the expected hydroxyl and guanidyl protons resonance frequencies. Histological study confirmed the specific neuronal expression of the transgene evidenced by the fluorescence signal from the td‐Tomato fluorophore fused to the polypeptide. The ability to image noninvasively a neuron‐specific CEST‐MRI reporter gene could offer valuable insights for further developments of gene therapy for neurological disorders.
- Open Access
- 24 October 2024
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 93 (3) , 1394-1410
Toward quantitative CEST imaging of glutamate in the mouse brain using a multi‐pool exchange model calibrated by 1H‐MRS
Purpose: To develop a CEST quantification model to map glutamate concentration in the mouse brain at 11.7 T, overcoming the limitations of conventional glutamate‐weighted CEST (gluCEST) contrast (magnetization transfer ratio with asymmetric analysis).Methods: 1H‐MRS was used as a gold standard for glutamate quantification to calibrate a CEST‐based quantitative pipeline. Joint localized measurements of Z‐spectra at B1 = 5 μT and quantitative 1H‐MRS were carried out in two voxels of interest in the mouse brain. A six‐pool Bloch‐McConnell model was found appropriate to fit experimental data. Glutamate exchange rate was estimated in both regions with this dedicated multi‐pool fitting model and using glutamate concentration determined by 1H‐MRS.Results: Glutamate exchange rate was estimated to be ˜1300 Hz in the mouse brain. Using this calibrated value, maps of glutamate concentration in the mouse brain were obtained by pixel‐by‐pixel fitting of Z‐spectra at B1 = 5 μT. A complementary study of simulations, however, showed that the quantitative model has high sensitivity to noise, and therefore, requires high‐SNR acquisitions. Interestingly, fitted [Glu] seemed to be overestimated compared to 1H‐MRS measurements, although it was estimated with simulations that the model has no intrinsic fitting bias with our experimental level of noise. The hypothesis of an unknown proton‐exchanging pool contributing to gluCEST signal is discussed.Conclusion: High‐resolution mapping of glutamate in the brain was made possible using the proposed calibrated quantification model of gluCEST data. Further studying of the in vivo molecular contributions to gluCEST signal could improve modeling.
- 24 October 2024
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 93 (3) , 1394-1410
Open AccessToward quantitative CEST imaging of glutamate in the mouse brain using a multi‐pool exchange model calibrated by 1H‐MRS
Purpose: To develop a CEST quantification model to map glutamate concentration in the mouse brain at 11.7 T, overcoming the limitations of conventional glutamate‐weighted CEST (gluCEST) contrast (magnetization transfer ratio with asymmetric analysis).Methods: 1H‐MRS was used as a gold standard for glutamate quantification to calibrate a CEST‐based quantitative pipeline. Joint localized measurements of Z‐spectra at B1 = 5 μT and quantitative 1H‐MRS were carried out in two voxels of interest in the mouse brain. A six‐pool Bloch‐McConnell model was found appropriate to fit experimental data. Glutamate exchange rate was estimated in both regions with this dedicated multi‐pool fitting model and using glutamate concentration determined by 1H‐MRS.Results: Glutamate exchange rate was estimated to be ˜1300 Hz in the mouse brain. Using this calibrated value, maps of glutamate concentration in the mouse brain were obtained by pixel‐by‐pixel fitting of Z‐spectra at B1 = 5 μT. A complementary study of simulations, however, showed that the quantitative model has high sensitivity to noise, and therefore, requires high‐SNR acquisitions. Interestingly, fitted [Glu] seemed to be overestimated compared to 1H‐MRS measurements, although it was estimated with simulations that the model has no intrinsic fitting bias with our experimental level of noise. The hypothesis of an unknown proton‐exchanging pool contributing to gluCEST signal is discussed.Conclusion: High‐resolution mapping of glutamate in the brain was made possible using the proposed calibrated quantification model of gluCEST data. Further studying of the in vivo molecular contributions to gluCEST signal could improve modeling.
- Open Access
- 13 February 2024
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 16, 1306312
The contribution of preclinical magnetic resonance imaging and spectroscopy to Huntington’s disease
Huntington’s disease is an inherited disorder characterized by psychiatric, cognitive, and motor symptoms due to degeneration of medium spiny neurons in the striatum. A prodromal phase precedes the onset, lasting decades. Current biomarkers include clinical score and striatal atrophy using Magnetic Resonance Imaging (MRI). These markers lack sensitivity for subtle cellular changes during the prodromal phase. MRI and MR spectroscopy offer different contrasts for assessing metabolic, microstructural, functional, or vascular alterations in the disease. They have been used in patients and mouse models. Mouse models can be of great interest to study a specific mechanism of the degenerative process, allow better understanding of the pathogenesis from the prodromal to the symptomatic phase, and to evaluate therapeutic efficacy. Mouse models can be divided into three different constructions: transgenic mice expressing exon-1 of human huntingtin (HTT), mice with an artificial chromosome expressing full-length human HTT, and knock-in mouse models with CAG expansion inserted in the murine htt gene. Several studies have used MRI/S to characterized these models. However, the multiplicity of modalities and mouse models available complicates the understanding of this rich corpus. The present review aims at giving an overview of results obtained using MRI/S for each mouse model of HD, to provide a useful resource for the conception of neuroimaging studies using mouse models of HD. Finally, despite difficulties in translating preclinical protocols to clinical applications, many biomarkers identified in preclinical models have already been evaluated in patients. This review also aims to cover this aspect to demonstrate the importance of MRI/S for studying HD.
- 13 February 2024
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 16, 1306312
Open AccessThe contribution of preclinical magnetic resonance imaging and spectroscopy to Huntington’s disease
Huntington’s disease is an inherited disorder characterized by psychiatric, cognitive, and motor symptoms due to degeneration of medium spiny neurons in the striatum. A prodromal phase precedes the onset, lasting decades. Current biomarkers include clinical score and striatal atrophy using Magnetic Resonance Imaging (MRI). These markers lack sensitivity for subtle cellular changes during the prodromal phase. MRI and MR spectroscopy offer different contrasts for assessing metabolic, microstructural, functional, or vascular alterations in the disease. They have been used in patients and mouse models. Mouse models can be of great interest to study a specific mechanism of the degenerative process, allow better understanding of the pathogenesis from the prodromal to the symptomatic phase, and to evaluate therapeutic efficacy. Mouse models can be divided into three different constructions: transgenic mice expressing exon-1 of human huntingtin (HTT), mice with an artificial chromosome expressing full-length human HTT, and knock-in mouse models with CAG expansion inserted in the murine htt gene. Several studies have used MRI/S to characterized these models. However, the multiplicity of modalities and mouse models available complicates the understanding of this rich corpus. The present review aims at giving an overview of results obtained using MRI/S for each mouse model of HD, to provide a useful resource for the conception of neuroimaging studies using mouse models of HD. Finally, despite difficulties in translating preclinical protocols to clinical applications, many biomarkers identified in preclinical models have already been evaluated in patients. This review also aims to cover this aspect to demonstrate the importance of MRI/S for studying HD.
- Open Access
- 16 January 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (1) , e0296790
Longitudinal MRI and 1H-MRS study of SCA7 mouse forebrain reveals progressive multiregional atrophy and early brain metabolite changes indicating early neuronal and glial dysfunction
SpinoCerebellar Ataxia type 7 (SCA7) is an inherited disorder caused by CAG triplet repeats encoding polyglutamine expansion in the ATXN7 protein, which is part of the transcriptional coactivator complex SAGA. The mutation primarily causes neurodegeneration in the cerebellum and retina, as well as several forebrain structures. The SCA7140Q/5Q knock-in mouse model recapitulates key disease features, including loss of vision and motor performance. To characterize the temporal progression of brain degeneration of this model, we performed a longitudinal study spanning from early to late symptomatic stages using high-resolution magnetic resonance imaging (MRI) and in vivo 1H-magnetic resonance spectroscopy (1H-MRS). Compared to wild-type mouse littermates, MRI analysis of SCA7 mice shows progressive atrophy of defined brain structures, with the striatum, thalamus and cortex being the first and most severely affected. The volume loss of these structures coincided with increased motor impairments in SCA7 mice, suggesting an alteration of the sensory-motor network, as observed in SCA7 patients. MRI also reveals atrophy of the hippocampus and anterior commissure at mid-symptomatic stage and the midbrain and brain stem at late stage. 1H-MRS of hippocampus, a brain region previously shown to be dysfunctional in patients, reveals early and progressive metabolic alterations in SCA7 mice. Interestingly, abnormal glutamine accumulation precedes the hippocampal atrophy and the reduction in myo-inositol and total N-acetyl-aspartate concentrations, two markers of glial and neuronal damage, respectively. Together, our results indicate that non-cerebellar alterations and glial and neuronal metabolic impairments may play a crucial role in the development of SCA7 mouse pathology, particularly at early stages of the disease. Degenerative features of forebrain structures in SCA7 mice correspond to current observations made in patients. Our study thus provides potential biomarkers that could be used for the evaluation of future therapeutic trials using the SCA7140Q/5Q model.
- 16 January 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (1) , e0296790
Open AccessLongitudinal MRI and 1H-MRS study of SCA7 mouse forebrain reveals progressive multiregional atrophy and early brain metabolite changes indicating early neuronal and glial dysfunction
SpinoCerebellar Ataxia type 7 (SCA7) is an inherited disorder caused by CAG triplet repeats encoding polyglutamine expansion in the ATXN7 protein, which is part of the transcriptional coactivator complex SAGA. The mutation primarily causes neurodegeneration in the cerebellum and retina, as well as several forebrain structures. The SCA7140Q/5Q knock-in mouse model recapitulates key disease features, including loss of vision and motor performance. To characterize the temporal progression of brain degeneration of this model, we performed a longitudinal study spanning from early to late symptomatic stages using high-resolution magnetic resonance imaging (MRI) and in vivo 1H-magnetic resonance spectroscopy (1H-MRS). Compared to wild-type mouse littermates, MRI analysis of SCA7 mice shows progressive atrophy of defined brain structures, with the striatum, thalamus and cortex being the first and most severely affected. The volume loss of these structures coincided with increased motor impairments in SCA7 mice, suggesting an alteration of the sensory-motor network, as observed in SCA7 patients. MRI also reveals atrophy of the hippocampus and anterior commissure at mid-symptomatic stage and the midbrain and brain stem at late stage. 1H-MRS of hippocampus, a brain region previously shown to be dysfunctional in patients, reveals early and progressive metabolic alterations in SCA7 mice. Interestingly, abnormal glutamine accumulation precedes the hippocampal atrophy and the reduction in myo-inositol and total N-acetyl-aspartate concentrations, two markers of glial and neuronal damage, respectively. Together, our results indicate that non-cerebellar alterations and glial and neuronal metabolic impairments may play a crucial role in the development of SCA7 mouse pathology, particularly at early stages of the disease. Degenerative features of forebrain structures in SCA7 mice correspond to current observations made in patients. Our study thus provides potential biomarkers that could be used for the evaluation of future therapeutic trials using the SCA7140Q/5Q model.
- 26 April 2022
- Published by Wolters Kluwer Health in European Journal of Emergency Medicine
- Vol. 29 (3) , 230-232
Pre-hospital emergency medicine in Belgium: an overview of an evolving medical and paramedical organization
- 26 April 2022
- Published by Wolters Kluwer Health in European Journal of Emergency Medicine
- Vol. 29 (3) , 230-232
Pre-hospital emergency medicine in Belgium: an overview of an evolving medical and paramedical organization
- 17 March 2022
- Published by Oxford University Press (OUP) in Brain
- Vol. 146 (1) , 149-166
Reactive astrocytes promote proteostasis in Huntington’s disease through the JAK2-STAT3 pathway
Huntington’s disease is a fatal neurodegenerative disease characterized by striatal neurodegeneration, aggregation of mutant Huntingtin and the presence of reactive astrocytes. Astrocytes are important partners for neurons and engage in a specific reactive response in Huntington’s disease that involves morphological, molecular and functional changes. How reactive astrocytes contribute to Huntington’s disease is still an open question, especially because their reactive state is poorly reproduced in experimental mouse models. Here, we show that the JAK2-STAT3 pathway, a central cascade controlling astrocyte reactive response, is activated in the putamen of Huntington’s disease patients. Selective activation of this cascade in astrocytes through viral gene transfer reduces the number and size of mutant Huntingtin aggregates in neurons and improves neuronal defects in two complementary mouse models of Huntington’s disease. It also reduces striatal atrophy and increases glutamate levels, two central clinical outcomes measured by non-invasive magnetic resonance imaging. Moreover, astrocyte-specific transcriptomic analysis shows that activation of the JAK2-STAT3 pathway in astrocytes coordinates a transcriptional program that increases their intrinsic proteolytic capacity, through the lysosomal and ubiquitin-proteasome degradation systems. This pathway also enhances their production and exosomal release of the co-chaperone DNAJB1, which contributes to mutant Huntingtin clearance in neurons. Together, our results show that the JAK2-STAT3 pathway controls a beneficial proteostasis response in reactive astrocytes in Huntington’s disease, which involves bi-directional signalling with neurons to reduce mutant Huntingtin aggregation, eventually improving disease outcomes.
- 17 March 2022
- Published by Oxford University Press (OUP) in Brain
- Vol. 146 (1) , 149-166
Reactive astrocytes promote proteostasis in Huntington’s disease through the JAK2-STAT3 pathway
Huntington’s disease is a fatal neurodegenerative disease characterized by striatal neurodegeneration, aggregation of mutant Huntingtin and the presence of reactive astrocytes. Astrocytes are important partners for neurons and engage in a specific reactive response in Huntington’s disease that involves morphological, molecular and functional changes. How reactive astrocytes contribute to Huntington’s disease is still an open question, especially because their reactive state is poorly reproduced in experimental mouse models. Here, we show that the JAK2-STAT3 pathway, a central cascade controlling astrocyte reactive response, is activated in the putamen of Huntington’s disease patients. Selective activation of this cascade in astrocytes through viral gene transfer reduces the number and size of mutant Huntingtin aggregates in neurons and improves neuronal defects in two complementary mouse models of Huntington’s disease. It also reduces striatal atrophy and increases glutamate levels, two central clinical outcomes measured by non-invasive magnetic resonance imaging. Moreover, astrocyte-specific transcriptomic analysis shows that activation of the JAK2-STAT3 pathway in astrocytes coordinates a transcriptional program that increases their intrinsic proteolytic capacity, through the lysosomal and ubiquitin-proteasome degradation systems. This pathway also enhances their production and exosomal release of the co-chaperone DNAJB1, which contributes to mutant Huntingtin clearance in neurons. Together, our results show that the JAK2-STAT3 pathway controls a beneficial proteostasis response in reactive astrocytes in Huntington’s disease, which involves bi-directional signalling with neurons to reduce mutant Huntingtin aggregation, eventually improving disease outcomes.
- Open Access
- 11 February 2022
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 31 (21) , 3581-3596
Longitudinal multimodal MRI characterization of a knock-in mouse model of Huntington’s disease reveals early gray and white matter alterations
Pathogenesis of the inherited neurodegenerative disorder Huntington’s disease (HD) is progressive with a long presymptomatic phase in which subtle changes occur up to 15 years before the onset of symptoms. Thus, there is a need for early, functional biomarker to better understand disease progression and to evaluate treatment efficacy far from onset. Recent studies have shown that white matter may be affected early in mutant HTT gene carriers. A previous study performed on 12 months old Ki140CAG mice showed reduced glutamate level measured by Chemical Exchange Saturation Transfer of glutamate (gluCEST), especially in the corpus callosum. In this study, we scanned longitudinally Ki140CAG mice with structural MRI, diffusion tensor imaging, gluCEST and magnetization transfer imaging, in order to assess white matter integrity over the life of this mouse model characterized by slow progression of symptoms. Our results show early defects of diffusion properties in the anterior part of the corpus callosum at 5 months of age, preceding gluCEST defects in the same region at 8 and 12 months that spread to adjacent regions. At 12 months, frontal and piriform cortices showed reduced gluCEST, as well as the pallidum. MT imaging showed reduced signal in the septum at 12 months. Cortical and striatal atrophy then appear at 18 months. Vulnerability of the striatum and motor cortex, combined with alterations of anterior corpus callosum, seems to point out the potential role of white matter in the brain dysfunction that characterizes HD and the pertinence of gluCEST and DTI as biomarkers in HD.
- 11 February 2022
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 31 (21) , 3581-3596
Open AccessLongitudinal multimodal MRI characterization of a knock-in mouse model of Huntington’s disease reveals early gray and white matter alterations
Pathogenesis of the inherited neurodegenerative disorder Huntington’s disease (HD) is progressive with a long presymptomatic phase in which subtle changes occur up to 15 years before the onset of symptoms. Thus, there is a need for early, functional biomarker to better understand disease progression and to evaluate treatment efficacy far from onset. Recent studies have shown that white matter may be affected early in mutant HTT gene carriers. A previous study performed on 12 months old Ki140CAG mice showed reduced glutamate level measured by Chemical Exchange Saturation Transfer of glutamate (gluCEST), especially in the corpus callosum. In this study, we scanned longitudinally Ki140CAG mice with structural MRI, diffusion tensor imaging, gluCEST and magnetization transfer imaging, in order to assess white matter integrity over the life of this mouse model characterized by slow progression of symptoms. Our results show early defects of diffusion properties in the anterior part of the corpus callosum at 5 months of age, preceding gluCEST defects in the same region at 8 and 12 months that spread to adjacent regions. At 12 months, frontal and piriform cortices showed reduced gluCEST, as well as the pallidum. MT imaging showed reduced signal in the septum at 12 months. Cortical and striatal atrophy then appear at 18 months. Vulnerability of the striatum and motor cortex, combined with alterations of anterior corpus callosum, seems to point out the potential role of white matter in the brain dysfunction that characterizes HD and the pertinence of gluCEST and DTI as biomarkers in HD.